Teleflex Incorporated (NYSE:TFX) Director Benson Smith sold 9,331 shares of the business’s stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $250.31, for a total value of $2,335,642.61. Following the completion of the sale, the director now directly owns 77,887 shares in the company, valued at approximately $19,495,894.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Benson Smith also recently made the following trade(s):
- On Monday, September 17th, Benson Smith sold 9,331 shares of Teleflex stock. The shares were sold at an average price of $266.73, for a total value of $2,488,857.63.
- On Monday, August 27th, Benson Smith sold 9,331 shares of Teleflex stock. The shares were sold at an average price of $247.69, for a total value of $2,311,195.39.
- On Monday, August 6th, Benson Smith sold 9,331 shares of Teleflex stock. The shares were sold at an average price of $241.84, for a total value of $2,256,609.04.
- On Monday, July 16th, Benson Smith sold 9,331 shares of Teleflex stock. The stock was sold at an average price of $272.07, for a total value of $2,538,685.17.
Teleflex stock opened at $248.25 on Friday. Teleflex Incorporated has a twelve month low of $227.52 and a twelve month high of $288.78. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.45 and a current ratio of 2.21. The firm has a market cap of $12.19 billion, a PE ratio of 29.55, a P/E/G ratio of 1.87 and a beta of 1.12.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 2nd. The medical technology company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.06. Teleflex had a return on equity of 17.32% and a net margin of 3.78%. The business had revenue of $609.87 million for the quarter, compared to analyst estimates of $615.97 million. During the same quarter in the prior year, the company earned $2.04 earnings per share. The company’s revenue was up 15.4% on a year-over-year basis. Analysts predict that Teleflex Incorporated will post 9.82 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 14th. Stockholders of record on Wednesday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend was Tuesday, August 14th. Teleflex’s dividend payout ratio is currently 16.19%.
A number of research firms have recently weighed in on TFX. Needham & Company LLC raised Teleflex from a “buy” rating to a “strong-buy” rating and upped their price objective for the stock from $279.00 to $300.00 in a research report on Monday, September 10th. ValuEngine raised Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. TheStreet lowered Teleflex from a “b” rating to a “c+” rating in a research report on Friday, August 3rd. Finally, Morgan Stanley cut their price objective on Teleflex from $310.00 to $295.00 and set an “overweight” rating on the stock in a research report on Friday, August 3rd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teleflex has an average rating of “Buy” and an average target price of $289.25.
Institutional investors have recently bought and sold shares of the company. Summit Trail Advisors LLC grew its stake in shares of Teleflex by 23,599.0% during the first quarter. Summit Trail Advisors LLC now owns 1,181,159 shares of the medical technology company’s stock worth $1,181,000 after purchasing an additional 1,176,175 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Teleflex by 0.3% during the second quarter. Bank of New York Mellon Corp now owns 548,319 shares of the medical technology company’s stock worth $147,064,000 after purchasing an additional 1,783 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Teleflex by 1,177.7% during the second quarter. Marshall Wace LLP now owns 342,631 shares of the medical technology company’s stock worth $91,897,000 after purchasing an additional 315,814 shares in the last quarter. Morgan Stanley grew its stake in shares of Teleflex by 4.3% during the second quarter. Morgan Stanley now owns 292,030 shares of the medical technology company’s stock worth $78,325,000 after purchasing an additional 12,068 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Teleflex during the second quarter worth $60,706,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Article: Do Tariffs Work?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.